SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Saturday, March 16, 2013

Guest Post: Kallam Anji Reddy: 1941 - 2013

Posted on 9:56 AM by Unknown
Dr. Anji Reddy, Image from here
As many of you may have read in the newspapers, Dr. Anji Reddy, the founder of Dr. Reddy's Laboratories Ltd., one of India's largest pharmaceutical companies is no more. He passed away on March 15, 2013 at 3:45 PM after a battle with liver cancer. As one of the biggest names in India's pharmaceutical industry, Dr. Reddy had a significant influence on India's patent policy and unlike most other generics, he invested substantially in trying to create a new drug molecule. 

We requested Raghu Cidambi, a former advisor at Dr. Reddy's Laboratories to write an obituary for Dr. Reddy, especially his impact on the IP debate in India. 

Cidambi has also written another obituary in the Hindu Business Line which can be accessed over here.  

Kallam Anji Reddy: 1941 - 2013
by 
Raghu Cidambi

One would never have thought that Dr. Kallam Anji Reddy was a septuagenarian. The passage of years did little to diminish the spring in his step or his zest for life. And above all, it only strengthened his resolve to discover news drugs and put India among the front-ranking nations in the world of pharmaceutical producers. 

When Dr Anji Reddy started out as an entrepreneur in 1976 to make bulk drugs after a stint in the public sector Indian Drugs and Pharmaceuticals, he wrote out his dream which became his mission in life: 

“to bring new molecules into the country at a price the common man would afford” 

Thirteen years later, in 1989, Dr. Anji Reddy created a sensation by halving the price of norfloxacin, the newest antibiotic at that time. And he followed it up with a slew of generics, many of them introduced into the country for the first time, and all of them at affordable prices. 

He often joked about the pricing of drugs by innovators. ‘You know ranitidine is an anti-ulcer drug. It was priced at one dollar in the US. At that price it would have given people ulcers in India, not cured them’. His pricing formula was simple. If the innovator priced the drug at a dollar in the US, he thought it would be reasonable to price it at a rupee in India. In those days, his mantra was ‘One dollar is one rupee’. Affordable pricing of new generic medicines became the norm and India became the ‘pharmacy of the world’. 

Just a few years later, the great patent debate was hotting up with reports appearing in the newspapers of the discussions of the likely contours of the TRIPS agreement. Much of the country seemed to be up in arms against the reintroduction of patents for medicinal products. Many politicians criticised the proposed changes vehemently, fearing that drugs would become prohibitively expensive. The generic industry feared that their business would be jeopardy. And the newspapers added to the alarm. 

In the midst of all this, Dr. Anji Reddy delivered the Presidential Address at the Indian Pharmaceutical Association in January 1993. He went against the grain of the dominant view and bluntly said that “issue before us is not whether to accept the patent regime but a question of when it will be accepted.” He then went on to outline the feasibility of drug discovery research in India and urged its consideration. Such ideas were not even passing thoughts in most of the industry and the speech was met with open disbelief and scepticism. 

Dr. Anji Reddy’s exhortations were not merely brave words. He had already set up a discovery laboratory. By 1997, he had licensed an insulin sensitizer to Novo Nordisk, the world leader in diabetes. The new molecule was in the same class as Takeda’s pioglitazone and SmithKline Beecham’s rosiglitazone and called balaglitazone, in honour of the Lord at Tirupati. This was a first for any Indian company. 

Seemingly better things were to follow. In August 1998, Dr. Reddy’s licensed ragalitazar, a first-in-class molecule, again for the treatment for diabetes. This was a truly a significant scientific achievement by any standard. Novo snapped it up and the animal data was so impressive that balaglitazar was discontinued and the development of ragaglitazar proceeded apace. Dr. Reddy’s retained the right to market the product in India – ‘Of course, we must market it in India’, Dr. Anji Reddy declared. ‘It needs to be priced affordably.’ Unfortunately, the molecule failed at the final safety hurdle. 

All through the 1990s and the turn of the millenium, Dr. Anji Reddy was a vocal votary of patents. ‘Do you want the world to think we are brainless?’ was his line in many interviews and public meetings while arguing for patents. 

Many were puzzled by the apparent contradiction between the commitment to affordable medicine, the promotion of patents and Dr. Reddy’s Laboratories spectacular financial performance. To Dr. Anji Reddy, there was nothing odd about it. He often quoted George Merck: 

“We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered that, the larger they have been.”

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Obituary | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ▼  March (66)
      • US Department of Justice conducts review of IPXI
      • Public health activists lose challenge against Gil...
      • Bombay HC restrains the release of any trailers/te...
      • SpicyIP Tidbit: Viacom restrained from using 'Naut...
      • Recent decision on Protection of Plant Varieties A...
      • Ericsson sues Micromax over SEPs in 100-crore Pate...
      • Full Bench Delhi HC (Design Act)- Reckitt Benkise...
      • Guest Post: U.S. Supreme Court hears arguments in ...
      • Patent Office publishes final version of Guideline...
      • Joint Committees related to Trademark Matters
      • SpicyIP Weekly Review (March- Week 4)
      • Copyright Constitutionality Challenges
      • Statistics of patent grants in India
      • Breaking News: India's Copyright Amendments Challe...
      • Copyright Rules, 2013 designed to fail the Copyrig...
      • Copy of the Copyright Rules, 2013
      • 'Mad Men' controversy
      • A clarification on the Fox-‘Knockout’ copyright di...
      • The recent AMUL-IMUL trademark controversy
      • India’s patent policy: Big Pharma’s grouse?
      • Pratibha Syntex lawsuit still pending before the D...
      • SpicyIP Tidbit: An IP Thriller from an IP lawyer
      • US Supreme Court Supports Parallel Imports: Lesson...
      • IPAB’s first CL decision, resounding emphasis on p...
      • Government notifies Copyright Rules, 2013
      • SpicyIP Weekly Review (March Week 3)
      • Knock(ed) Out!
      • US Patent Reform - 2013: A brief look at the AIA
      • Breaking News: Second Compulsory Licensing Applica...
      • Zanjeer Remake Row before the Bombay HC
      • Guest Post: Kallam Anji Reddy: 1941 - 2013
      • EU Human Rights Court justifies The Pirate Bay con...
      • Breaking Hot News: Madras High Court strikes down ...
      • DU Photocopy Case: Academicians and Authors expres...
      • Bombay HC: Publication of Examination Report on we...
      • Breaking "Hot" News: A "Star" Win for Unfair Compe...
      • The role played by Microsoft in getting California...
      • An outrageous Californian attempt at extra-territo...
      • Standing Committee Report on ‘The Universities Res...
      • Standing Committee Report on ‘The Universities Res...
      • Spicy IP Weekly Review: March 2nd Week
      • Latest update from Campaign for affordable trastuz...
      • A recent study shows that U.S. firms don’t actuall...
      • A Tantalising Copyright Offer: Lessons from Canada...
      • Auditing the worldwide litigation involving ‘Basma...
      • ‘Rethinking the data exclusivity debate in India’ ...
      • UOI v. Malhotra Book Depot- restoration of trademark.
      • Call for Papers: IIT Bombay and MHRD jointly annou...
      • Guest Post: Eye witness account of India's first c...
      • Guest Post: Eye witness account of India's first c...
      • Bombay High Court – Are courts allowed to examine ...
      • Life of P.I. - Keynote address by Justice Prabha S...
      • SpicyIP Event: Announcing Expert Speaker Panel for...
      • SpicyIP Tidbit: Saregama loses copyright claim for...
      • Guest Post: Book Review - V.J. Taraporevala, Law o...
      • Blocking order issued against six UK ISP's by Engl...
      • Film release strategies and anti-competitive pract...
      • Compulsory Licensing is Not a Bad Word!
      • ‘First set up the labs, then dream the Nobel’
      • Spicy IP Weekly review (March Week 1)
      • December 2012: Controller's decisions at the IPO
      • Patents vs. Patients: Department of Pharmaceutical...
      • SpicyIP Tidbit: ViiV Healthcare collaborates with ...
      • Breaking News: Student Association Impleaded in Ac...
      • Kerala State Central Library digitizes Rare Books ...
      • Bombay High Court Decision on Trademark Infringeme...
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.